Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 147 Matches

Vancomycin_V14R1_AstraZeneca_20200327
Vancomycin for pediatric predictions. https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/psp4.12101
Lamivudine_V18R1_Simcyp_20200212
FO, mainly renally excreted. Has been used with HV, pregnancy population and elderly population.
Bergamottin_V19R1_AstraZeneca_20210423
CYP inhibitor found in grapefruit juice. AstraZeneca file.

Brand Name(s) include: N/A

Disease: Malaria

Drug Class: Antimalarials

Date Updated: June 2021

Related Files: Amodiaquine (parent drug)

The model at-a-glance

  Absorption Model

  • N/A

  Volume of Distribution

  • Minimal PBPK (Method 2)

  Route of Elimination

  • CLPO (non-specific) and renal clearance

  Perpetrator DDI

  • CYP2D6

  Validation

  • Simulations based on 1 clinical study describing multiple dose exposure of DHEA and 1 DDI study where formation of DHEA was the victim of a CYP2C9 mediated DDI were both within 1.5-fold of the observed values.

  Limitations

  • Clinical data has not been used to verify DEAQ as a perpetrator of CYP2D6-mediated DDIs

  Updates in V19

  • Updated DEAQ Ki for CYP2D6

 

|<

<

16

17

18

19

20

21

22

23

24

25

26

27

28

29

>

>|